ImpediMed

What ImpediMed does

ImpediMed Limited is a publicly traded medical-device company (ASX: IPD; OTC: IPDQF) founded in 1999/2000 and headquartered in Sydney, Australia, with US operations centered in Carlsbad, California. The company designs and manufactures the SOZO Digital Health Platform, the only FDA-cleared Bioimpedance Spectroscopy (BIS) technology that non-invasively measures 256 frequencies in a single rapid scan to separate intra- and extracellular fluid for whole-body composition profiling. SOZO runs a portfolio of FDA-cleared analysis modules: L-Dex for early-stage lymphedema detection, BodyComp and Segmental BodyComp for body composition monitoring, and HF-Dex for heart failure fluid management, paired with the MySOZO patient app and ImpediMed Academy provider-training portal.

The company monetizes through a mix of capital-hardware sales of SOZO devices, recurring cloud/subscription analytics on the SOZO platform, and implementation and training services, with pricing quoted on a per-engagement basis. ImpediMed sells primarily through an enterprise field-sales motion targeting US health systems, hospitals, and oncology practices, anchored on clinical evidence (the PREVENT Trial, NCCN Guidelines, NAPBC Standards) and a US reimbursement footprint that has reached 93% of covered lives for breast cancer-related lymphedema.

Its customer base spans four segments — cancer survivorship (primary), heart failure management, medical weight management (including GLP-1 monitoring), and wellness/longevity — served via direct sales and a provider-finder network. ImpediMed employs 51–100 people, is led by CEO Erik Anderson (appointed April 2026, previously at Hologic), and has raised approximately $30 million across a February 2025 SWK Holdings debt facility and a May 2026 equity placement to fund US commercial expansion.

Name

ImpediMed

Legal name

ImpediMed Limited

Website

https://impedimed.com.au

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

ImpediMed designs and commercializes the FDA-cleared SOZO Digital Health Platform, the only Bioimpedance Spectroscopy device for fluid-status and body-composition monitoring, sold primarily to US oncology, cardiology, weight-management, and wellness providers.

Ownership category

akta.pro rank

Product category

Medical Bioimpedance Spectroscopy Devices

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (3391)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Release Testing & Batch Certification (QC) (HLAGADAC)

akta.pro secondary industry

Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF)

Keywords

• Medical bioimpedance devices
• Lymphedema detection systems
• Body composition analyzers
• Heart failure monitoring devices
• Clinical spectroscopy platforms

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. SOZO Device Sales: Sale of SOZO Digital Health Platform hardware devices used in clinical settings for BIS measurements.
2. Software/Subscription Services: Subscription-based software analytics including L-Dex Analysis, BodyComp Analysis, HF-Dex Analysis, and Segmental BodyComp Analysis delivered through the cloud-connected SOZO platform.
3. Implementation and Training Services: Professional services supporting clinical implementation, training, and onboarding of the SOZO platform in healthcare facilities.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

ImpediMed designs and manufactures the FDA-cleared SOZO Digital Health Platform, a medical Bioimpedance Spectroscopy (BIS) device that measures 256 frequencies in a single rapid scan to deliver non-invasive fluid status and tissue composition analysis. The platform runs multiple clinical applications including L-Dex Analysis for lymphedema detection, BodyComp and Segmental BodyComp for body composition monitoring, and HF-Dex Analysis for heart failure fluid management, sold to healthcare providers in oncology, cardiology, and medical weight management settings.

Product overview

ImpediMed offers the SOZO Digital Health Platform as its core FDA-cleared Bioimpedance Spectroscopy (BIS) product, which measures 256 frequencies to separate intra- and extracellular fluid for accurate whole-body composition profiling. The platform integrates multiple analysis modules: L-Dex Analysis for lymphedema detection, BodyComp Analysis and Segmental BodyComp Analysis for body composition monitoring, and HF-Dex Analysis for heart failure management. These modules work together within the unified cloud-connected SOZO platform to deliver real-time, personalized fluid and tissue monitoring across cancer survivorship, heart health, medical weight management, and wellness applications.

Differentiator

Problem solved

Functional benefit

Brands

• SOZO Digital Health Platform: FDA-cleared bioimpedance spectroscopy technology platform that non-invasively measures fluid status and tissue composition
• L-Dex Analysis
• BodyComp Analysis
• HF-Dex Analysis
• Segmental BodyComp Analysis
• MySOZO

Products and services

• SOZO Digital Health Platform FDA-cleared Bioimpedance Spectroscopy (BIS) platform that non-invasively measures fluid status and tissue composition by scanning 256 frequencies in a single rapid scan, with a cloud-connected interface delivering actionable data at the point of care for healthcare providers.
• L-Dex Analysis for Lymphedema Quantitative BIS-based measurement for detecting lymphedema at the subclinical stage to prevent progression to a chronic condition; used by oncology and survivorship care providers.
• BodyComp Analysis BIS-based analysis that tracks fluid volumes and tissue composition to inform clinical decisions and motivate patient compliance in weight management and clinical care.
• Segmental BodyComp Analysis Provides localized segmental fluid and tissue composition measurements for targeted clinical assessment on the SOZO platform.
• HF-Dex Analysis for Heart Failure BIS-based analysis that captures dynamic changes in fluid volume to track disease progression and treatment success in heart failure patients.
• Lymphedema Prevention Program Structured clinical program using the SOZO platform to reduce the risk of lymphedema development in at-risk patients, particularly those recovering from cancer treatment.

Quantifiable outcome

• Up to 80% of breast cancer patients at risk for lymphedema depending on treatment
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• InBody: InBody manufactures bioelectrical impedance analysis devices for body composition and fluid management. It competes head-to-head with SOZO in clinical body composition monitoring, though using BIA rather than BIS technology.
• Tactile Medical: Tactile Medical focuses on lymphedema and chronic edema management through pneumatic compression devices. It targets the same breast cancer survivorship and lymphedema patient population as ImpediMed's L-Dex program.
• Tanita: Tanita is a global manufacturer of BIA body composition monitors used in clinical and wellness settings. It competes with SOZO in body composition analysis, though primarily at the lower-frequency BIA technology tier.
• SECA: SECA produces medical-grade body composition analyzers using BIA, serving hospitals and clinical practices. It overlaps with ImpediMed in clinical body composition measurement for oncology, nephrology, and nutrition.
• RJL Systems: RJL Systems manufactures bioimpedance analyzers for clinical and research body composition. It is a direct BIS/BIA technology competitor in the same medical and research end markets.
• Bodystat: Bodystat produces bioimpedance analyzers for clinical body composition and fluid status assessment. It is a comparable specialist in BIS/BIA technology for medical and research applications.
• Akern: Akern manufactures BIA devices focused on body composition and fluid analysis for clinical and research use. It competes with SOZO in the same bioimpedance measurement category.

Broad incumbents

• Hologic: Hologic is a large women's health and diagnostics incumbent with a leading breast cancer franchise. ImpediMed's new CEO Erik Anderson led significant business units there, and Hologic's installed base of breast cancer providers is a natural channel for SOZO expansion.
• GE Healthcare: GE Healthcare is a broad incumbent in medical imaging, patient monitoring, and clinical analytics. It does not offer a direct BIS competitor but provides overlapping capabilities in patient monitoring and clinical decision support.
• Philips: Philips is a diversified health technology incumbent with patient monitoring and clinical informatics offerings. It does not specialize in bioimpedance but addresses overlapping clinical workflows in hospitals where ImpediMed sells SOZO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@impedimed
• Facebookfacebook.com/impedimed
• LinkedInlinkedin.com/company/145185
• Instagraminstagram.com/impedimedhealth
• Xx.com/impedimed

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImpediMed